Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-706 combination therapy in advanced digestive system tumors
CTR20253728Phase 2Active
- Sponsor
- 3SBio
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-706 in gastrointestinal cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), sponsored by 3SBio. Started Oct 2025; status: active.
02
Drugs
SSGJ-706
03
Conditions
gastrointestinal cancergastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20253728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253728.